$RNVA showing a loss, Press Release: Rennova Health

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz JAVA1 #12612
$RNVA showing a loss,

Press Release: Rennova Health Reports Second Quarter 2016 Financial Results
41 minutes ago - DJNF
Rennova Health Reports Second Quarter 2016 Financial Results

Conference call begins at 11:00 a.m. Eastern time today

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--August 15, 2016--

Rennova Health, Inc. (NASDAQ:RNVA) (NASDAQ:RNVAZ), a vertically integrated provider of industry-leading diagnostics and supportive software ("Rennova" or the "Company", reports financial results for the three and six months ended June 30, 2016, and provides a business update.

Business highlights for the second quarter of 2016 and recent weeks include:

-- Converted approximately $2.0 million of liabilities into equity in August

2016

-- Signed an agreement with Academy Medical to provide laboratory services

to U.S. federal government customers in July 2016

-- Completed a public equity raise totaling $8.6 million in gross proceeds

in July 2016

-- Acquired Hartford Healthcare Corporation's interest in Genomas, Inc., a

laboratory based in Connecticut that specializes in pharmacogenomics

-- Entered into a preferred provider network agreement with Three Rivers

Provider Network

-- Added electronic medication management functionality (eMAR) to the

Company's flagship M2Select electronic health record (EHR) product

Financial highlights for the second quarter of 2016 compared with the first quarter of 2016 include:

-- Net revenues of $3.1 million, compared with $1.9 million

-- Clinical Laboratory Operations net revenue of $2.5 million, compared with

$1.5 million

-- Supportive Software Solutions net revenues of $0.6 million, compared with

$0.5 million

-- Decision Support and Informatics net revenues of $0.2 million, compared

with $0.2 million

-- Gross margin of 87.2%, compared with 70.0%

Financial highlights for the second quarter of 2016 compared to the second quarter of 2015 include:

-- Net revenues of $3.1 million, compared with $9.4 million

-- Clinical Laboratory Operations net revenue of $2.5 million, compared with

$8.9 million

-- Supportive Software Solutions net revenues of $0.6 million, compared with

$0.9 million

-- Decision Support and Informatics net revenues of $0.2 million, compared

with no revenue

-- Gross margin of 87.2%, compared with 71.6%

Management Commentary

"Our second quarter has been in keeping with the turnaround we forecasted during our first quarter 2016 investor conference call in May, " stated Seamus Lagan, Rennova's Chief Executive Officer. "We have made significant progress in growing our core business of toxicology testing. We continue to add EHR customers to our software division and in the last few weeks we hired a professional to lead our billing services for substance abuse facilities, from which we are experiencing strong demand for integrated services."

"I am particularly pleased with the success we are having adding new payer contracts. These contracts continue to expand our target market and provide more predictable and reliable payments for diagnostic services. As an example of this success, we achieved a 63% increase in net revenues for the second quarter 2016 versus the first quarter. This increase substantiates our belief that although year-over-year results are down, we have begun to experience the turnaround forecasted," Mr. Lagan said.

"The sector in which we operate continues to be impacted by compliance matters, with many insurance companies now actively pursuing 'bad-actors' through the courts for reparation. Our focus on compliance, along with our extensive offering of testing services, which now includes pharmacogenomics tests, have resulted in a number of attractive new contracts with reliable payers over the past several months. For example, just last week we announced a contract with Academy Medical to promote the sale of our services to the U.S. federal government. We do not believe we would have obtained this contract without our exceptional focus on compliance. We expect to sign additional in-network contracts throughout the year."

"In March, we announced an alliance with Genomas to offer their revolutionary PhyzioType Systems for DNA-guided management and prescription of drugs. Subsequently, within the past month, we significantly strengthened our relationship by purchasing Hartford Healthcare Corporation's interest in Genomas. We now expect to accelerate our provision of diagnostics for DNA-guided management and prescription of drugs. These products provide guidance to physicians so that they may select the safest and most effective drugs to improve patient outcomes and enhance patient compliance. We will continue to expand this product offering in the coming weeks."

Mr. Lagan added, "During the second quarter we added eMAR functionality to our flagship M2Select EHR solution, which automates the process of monitoring patient medications, reducing the risk of medication dispensing errors. Partnering with our EHR clients is ongoing, and we have developed and improved our offerings during the second quarter. We are excited about the creation of a more sustainable relationship with our customers because of our growing ability to provide this software and integrated services."

Commenting on expectations for the remainder of the year, Mr. Lagan said, "We are securing additional customers -- June was the most active month of onboarding new customers in two years. In addition, we are confident that the growth in core toxicology diagnostics, combined with our investment in Genomas, will provide additional revenue and open new market segments over the coming months. We are continuing to explore and develop new revenue sources for diagnostics, including direct-to-consumer testing."

Mr. Lagan concluded, "We also continue to monitor our efficiency and expect that the cost-containment measures we have taken in recent months, which total $2.4 million annually, will further manifest themselves in our financial performance in the coming quarters. We anticipate that our current growth, combined with ongoing efforts to contain costs, will see us back to cash flow break even in the next few months."

Financial Results

Net revenues for the second quarter of 2016 were $3.1 million, compared with $9.4 million for the second quarter of 2015. Clinical Laboratory Operations revenues for the second quarter of 2016 were $2.5 million, compared with $8.9 million for the second quarter of 2015, a decrease of 72%. The decrease was primarily due to a decline in insured test volume, partially offset by an increase in the net revenue per insured test. During the first quarter of 2015 the Company transitioned a significant portion of its testing from external reference laboratories to internal processing, which resulted in a $0.5 million decrease in direct costs of revenues, or a 62% decrease in direct costs per sample. Total samples processed declined 68% year-over-year, resulting in a $1.8 million decrease in direct costs of revenues.

Supportive Software Solutions net revenues were $0.6 million for the second quarter of 2016, compared with $0.9 million for the second quarter of 2015, a decline of 38%. The decline was due to a reduction in the amounts charged by the Supportive Software Solutions group to the Company's Clinical Laboratory Operations group, partially offset by $0.1 million of increased revenues generated by sales of the Company's Medical Mime product, which was launched in the fourth quarter of 2015. Decision Support and Informatics net revenues were $0.2 million for the second quarter of 2016, compared with no revenues in the prior year's second quarter, as this segment was created with the acquisition of CollabRx, Inc. in November 2015.

Operating expenses for the second quarter of 2016 were $8.1 million, compared with $14.0 million for the prior-year second quarter. The decrease was primarily due to a decline in direct costs of revenue of $2.3 million, a decline in general and administrative expenses of $3.5 million and a decline in sales and marketing expenses of $0.5 million, partially offset by a $0.6 engineering expense.

The Company reported other expense of $0.8 million for the second quarter of 2016, compared with $0.5 million for the second quarter of 2015. The increase was mainly due to an increase in interest expense of $1.5 million during the quarter, largely offset by a gain on the change in the value of derivative instruments of $1.2 million. The Company recognized no income tax expense or benefit for the second quarter of 2016, compared with an income tax benefit of $0.9 million for the second quarter of 2015.

Net loss attributable to common stockholders for the second quarter of 2016 was $5.9 million, or $0.40 per basic and diluted share, compared with a net loss attributable to common stockholders for the second quarter of 2015 of $5.1 million, or $0.42 per basic and diluted share.

Net revenues for the six months ended June 30, 2016 were $4.9 million, compared with $23.0 million for the six months ended June 30, 2015. The decline was primarily due to a decline in insured test volume in the Clinical Laboratory Operations segment. Operating expenses declined to $16.8 million for the six months ended June 30, 2016, compared with $25.4 million in the prior-year period. The decrease was largely due to a $5.7 million reduction in direct costs of revenue and a $3.2 million decrease in general and administrative costs. The net loss attributable to common stockholders was $10.1 million, or $0.69 per share, for the six months ended June 30, 2016, compared with a net loss attributable to common stockholders of $4.6 million, or $0.38 per basic and diluted share, for the prior-year period.

The Company had cash and cash equivalents of $0.5 million as of June 30, 2016, compared with $8.8 million as of December 31, 2015. Subsequent to the close of the second quarter, the Company closed an underwritten offering of common stock and warrants, from which the Company raised approximately $8.6 million in gross proceeds.

Non-GAAP Measures

(MORE TO FOLLOW) Dow Jones Newswires

August 15, 2016 08:30 ET (12:30 GMT)
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Madison Achieves Top Rank for Employment Opportunities

Updated Category News Views 256

Madison Tops Functional Employment Rankings Recently, Madison has been recognized as the leading metro area in the country for functional employment, a title derived from a comprehensive analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP). This achievement highlights Madison’s robust job growth, higher wage levels, and an overall favorable work...

Continue Reading
Investors Alert: Class Actions Against WEBTOON, Elanco, and Domino's

Updated Category News Views 131

Class Action Lawsuits Overview In recent developments, Bragar Eagel & Squire, P.C., a well-known shareholder rights law firm, has informed investors about multiple class action lawsuits filed against notable companies such as WEBTOON Entertainment, Inc. (NASDAQ: WBTN), Elanco Animal Health Incorporated (NYSE: ELAN), and Domino's Pizza, Inc. (NYSE: DPZ). Shareholders in...

Continue Reading
Navigating the New Multipolar Reality: Insights for Investors

Updated Category News Views 257

The Shift to a Multipolar World: What Investors Need to Know The global landscape has transformed, moving away from a system dominated by one major power to a multipolar world. This significant shift means that traditional geopolitical assumptions guiding investors are no longer reliable. Marko Papic, Chief Strategist at BCA Research, recently underscored this point in a...

Continue Reading
Jim Cramer Discusses Broadcom's Impact on Market Corrections

Updated Category News Views 211

Market Dynamics and Broadcom's Recent Performance As the Nasdaq 100 index faces a notable correction, Broadcom Inc. (NASDAQ: AVGO) has managed to stand out with a remarkable surge of 12.82% during after-hours trading. However, renowned market analyst Jim Cramer expresses skepticism regarding its ability to reverse the overall market decline. Understanding the Market...

Continue Reading
NSFOCUS Achieves 'Stars Companies' Recognition in DDoS Sector

Updated Category News Views 137

NSFOCUS Achieves Notable Recognition in Cybersecurity In a significant development, NSFOCUS has earned recognition as a 'Stars Company' in the DDoS Protection and Mitigation Security sector by the esteemed MarketsandMarkets' 360Quadrants platform. This accolade reflects NSFOCUS's unwavering commitment to innovation and excellence in delivering cutting-edge solutions for...

Continue Reading